These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 31439274)

  • 21. Microvascular outcomes in type 2 diabetes - Authors' reply.
    Zoungas S; Gerstein HC; Holman RR; Reaven P; Woodward M; Arima H; Coleman RL; Chalmers J;
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):580. PubMed ID: 28732664
    [No Abstract]   [Full Text] [Related]  

  • 22. Explaining the high rate of progression from prediabetes to type 2 diabetes in China - Authors' reply.
    Zhang L; Gong Q; Sun N; Ji L; Li G
    Lancet Diabetes Endocrinol; 2023 Nov; 11(11):794-795. PubMed ID: 37884323
    [No Abstract]   [Full Text] [Related]  

  • 23. Editorial: type 1 diabetes, microscopic colitis and the need to explore the complex mechanisms of this association-authors' reply.
    Kang X; Liu S; Ludvigsson JF
    Aliment Pharmacol Ther; 2023 Jun; 57(12):1459-1460. PubMed ID: 37243468
    [No Abstract]   [Full Text] [Related]  

  • 24. Screening for peripheral artery disease in people with diabetes: authors' reply.
    Vriens B; D'Abate F; Ozdemir BA; Fenner C; Maynard W; Budge J; Carradice D; Hinchliffe RJ
    Diabet Med; 2019 Feb; 36(2):257-258. PubMed ID: 30242908
    [No Abstract]   [Full Text] [Related]  

  • 25. The reconstructed natural history of type 1 diabetes mellitus.
    Pozzilli P; Signore A
    Nat Rev Endocrinol; 2019 May; 15(5):256-257. PubMed ID: 30858529
    [No Abstract]   [Full Text] [Related]  

  • 26. Controlled attenuation parameter for the assessment of fatty liver in patients with type 1 diabetes mellitus: which cutoffs to choose? Authors' reply.
    Grzelka-Woźniak A; Uruska A; Szymańska-Garbacz E; Araszkiewicz A; Jabłkowski M; Czupryniak L; Zozulińska-Ziółkiewicz D
    Pol Arch Intern Med; 2024 Jan; 134(1):. PubMed ID: 38284874
    [No Abstract]   [Full Text] [Related]  

  • 27. Data on diabetes-specific distress are needed to improve the quality of diabetes care - Authors' reply.
    Chan JCN; Lim LL; Shaw JE; Aguilar-Salinas CA; Gregg EW;
    Lancet; 2021 Jun; 397(10290):2150. PubMed ID: 34090602
    [No Abstract]   [Full Text] [Related]  

  • 28. Linoleic acid and diabetes prevention - Authors' reply.
    Wu JHY; Mozaffarian D
    Lancet Diabetes Endocrinol; 2018 Jan; 6(1):13. PubMed ID: 29273164
    [No Abstract]   [Full Text] [Related]  

  • 29. Novel diabetes subgroups - Authors' reply.
    Ahlqvist E; Prasad RB; Tuomi T; Rosengren A; Groop L
    Lancet Diabetes Endocrinol; 2018 Jun; 6(6):440-441. PubMed ID: 29803264
    [No Abstract]   [Full Text] [Related]  

  • 30. Authors' reply to Shang et al.
    Ciardullo S; Cannistraci R; Mazzetti S; Mortara A; Perseghin G
    Int J Cardiol; 2022 Nov; 366():49. PubMed ID: 35810920
    [No Abstract]   [Full Text] [Related]  

  • 31. Comment on "Renal abscess complicated by duodenal obstruction in a patient with obesity and type 2 diabetes mellitus treated with gliflozin". Authors' reply.
    Gierlikowski W; Rosiak G; Trautsolt-Jeziorska K; Rosłon M; Bednarczuk T
    Pol Arch Intern Med; 2018 Oct; 128(10):634-635. PubMed ID: 30387452
    [No Abstract]   [Full Text] [Related]  

  • 32. Insulin resistance underlying type 2 diabetes - Authors' reply.
    Schmidt MI; Bracco PA; Duncan BB
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):424-425. PubMed ID: 31103175
    [No Abstract]   [Full Text] [Related]  

  • 33. Insulin dosing guidance to optimise type 2 diabetes management - Authors' reply.
    Bergenstal RM; Johnson ML; Bashan E; Hodish I
    Lancet; 2019 Oct; 394(10206):1321. PubMed ID: 31609220
    [No Abstract]   [Full Text] [Related]  

  • 34. Association between 25-hydroxyvitamin D and type 2 diabetes--authors' reply.
    Forouhi NG; Sharp SJ; Ye Z; Imamura F; Burgess S
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):11-12. PubMed ID: 25555437
    [No Abstract]   [Full Text] [Related]  

  • 35. VLCD for weight loss and remission of type 2 diabetes? - Authors' reply.
    Taylor R; Adamson AJ; Sattar N; Lean MEJ; Mathers JC;
    Lancet; 2018 Oct; 392(10155):1307. PubMed ID: 30322575
    [No Abstract]   [Full Text] [Related]  

  • 36. Diabetes prevention in England - Authors' reply.
    Maruthappu M; Sood H; Obrien J; Keogh B
    Lancet Diabetes Endocrinol; 2015 Jul; 3(7):503. PubMed ID: 26138169
    [No Abstract]   [Full Text] [Related]  

  • 37. SGLT-2 inhibitors for people with type 2 diabetes - Authors' reply.
    Zelniker TA; Wiviott SD; Raz I; Sabatine MS
    Lancet; 2019 Aug; 394(10198):560-561. PubMed ID: 31423992
    [No Abstract]   [Full Text] [Related]  

  • 38. Authors' Reply to Gough: "Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes".
    Chatterjee S; Khunti K; Davies M
    Drugs; 2019 Apr; 79(6):683-684. PubMed ID: 30919304
    [No Abstract]   [Full Text] [Related]  

  • 39. Editorial: improvement of cardiovascular risk factor control in patients with type 2 diabetes and nonalcoholic fatty liver disease-time for action! Authors' reply.
    Zhang X; Wong GL; Wong VW; Yip TC
    Aliment Pharmacol Ther; 2023 May; 57(10):1172-1173. PubMed ID: 37094323
    [No Abstract]   [Full Text] [Related]  

  • 40. Comment on "Coronary artery calcium in type 2 diabetes: a nested case-control study": authors' reply.
    Sosnowski M; Kozakiewicz K; Syzdół M; Nadrowski P; Młynarski R; Brzoska J; Tendera M
    Pol Arch Med Wewn; 2013; 123(3):132-3. PubMed ID: 23535862
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.